Top 10 Companies in the Recombinant Non‑Glycosylated Protein Market (2026): Market Leaders Powering Global Biopharma

MARKET INSIGHTS

Global recombinant non‑glycosylated protein market was valued at USD 715.8 million in 2024. The market is projected to grow from USD 775.4 million in 2025 to USD 1.31 billion by 2032, exhibiting a CAGR of 8.2% during the forecast period.

Recombinant non‑glycosylated proteins are engineered therapeutic proteins produced through DNA technology without post‑translational glycosylation modifications. These proteins play critical roles in biopharmaceutical applications, particularly in treating conditions like cancer, blood disorders, and autoimmune diseases. Key product types include insulin, interferons, growth factors, and cytokines that maintain therapeutic efficacy without sugar chain attachments.

Recent industry developments include Pfizer’s 2024 expansion of its non‑glycosylated protein production capacity in Europe to meet growing oncology demand, reflecting the sector’s robust potential.

Recombinant Non‑Glycosylated Protein Market – View in Detailed Research Report

---

🔟 1. Pfizer Inc.

Headquarters: New York, United States
Key Offering: Interferons, growth factors, and other non‑glycosylated protein therapeutics

Pfizer has positioned itself as a leader in the non‑glycosylated protein arena through strategic investments in R&D and manufacturing infrastructure. The company’s 2024 expansion in Europe has increased capacity by 30%, enabling rapid scale‑up for oncology indications.

Sustainability & Growth Initiatives:

• Expansion of European production lines to support oncology and immunotherapy pipelines.
• Investment in CDMO partnerships to accelerate time‑to‑market.
• Commitment to ESG goals with reduced carbon footprint in production facilities.

---

9️⃣ 2. Sandoz International GmbH

Headquarters: Holzkirchen, Germany
Key Offering: Biosimilar non‑glycosylated proteins for diabetes and hematology

Sandoz leverages its global biosimilar expertise to deliver cost‑effective non‑glycosylated therapeutics. The company’s focus on regulatory‑streamlined development has accelerated approvals across the EU.

Sustainability & Growth Initiatives:

• Expansion of production capacity in Germany and Italy.
• Adoption of green manufacturing practices.
• Strategic alliances with academic institutions for pipeline development.

---

8️⃣ 3. Teva Pharmaceutical Industries Ltd.

Headquarters: Israel
Key Offering: Non‑glycosylated protein biosimilars for oncology and autoimmune disorders

Teva’s robust manufacturing footprint and strong R&D pipeline position it as a key player in the non‑glycosylated protein market. The company’s focus on innovative delivery platforms enhances therapeutic efficacy.

Sustainability & Growth Initiatives:

• Investment in advanced biomanufacturing facilities in Israel and the US.
• Implementation of circular economy principles in production.
• Collaboration with global partners to expand market reach.

---

7️⃣ 4. Amgen Inc.

Headquarters: Thousand Oaks, United States
Key Offering: Growth factors and cytokines for metabolic and inflammatory diseases

Amgen’s strong R&D capabilities and focus on protein engineering have driven innovation in non‑glycosylated therapeutics. The company’s emphasis on precision medicine aligns with market demand for tailored treatments.

Sustainability & Growth Initiatives:

• Expansion of biomanufacturing capacity in the US and Europe.
• Investment in renewable energy for production sites.
• Strategic collaborations with biotech startups.

---

6️⃣ 5. Biocon Ltd.

Headquarters: Bangalore, India
Key Offering: Non‑glycosylated protein biosimilars for diabetes and oncology

Biocon’s rapid scale‑up of production facilities in India has positioned it as a leading biosimilar manufacturer in the Asia‑Pacific region. The company’s focus on cost‑efficiency drives market penetration.

Sustainability & Growth Initiatives:

• Investment in state‑of‑the‑art fermentation technology.
• Adoption of water‑recycling and waste‑reduction protocols.
• Strategic partnerships with local universities.

---

5️⃣ 6. Dr. Reddy’s Laboratories Ltd.

Headquarters: Hyderabad, India
Key Offering: Non‑glycosylated protein therapies for hematology and metabolic disorders

Dr. Reddy’s leverages its global manufacturing network to deliver high‑quality non‑glycosylated proteins. The company’s focus on process optimization reduces production costs.

Sustainability & Growth Initiatives:

• Expansion of production capacity in India and the US.
• Implementation of green chemistry in upstream processes.
• Collaboration with CDMOs for accelerated development.

---

4️⃣ 7. F. Hoffmann‑La Roche Ltd.

Headquarters: Basel, Switzerland
Key Offering: Non‑glycosylated protein biologics for oncology and immunology

Roche’s strong portfolio of biologics and focus on antibody‑based therapies complement its non‑glycosylated protein segment, driving innovation in targeted treatments.

Sustainability & Growth Initiatives:

• Investment in scalable bioprocessing platforms.
• Commitment to carbon‑neutral operations by 2030.
• Strategic alliances with research institutions.

---

3️⃣ 8. Celltrion Inc.

Headquarters: Seoul, South Korea
Key Offering: Non‑glycosylated protein biosimilars for rare diseases and oncology

Celltrion’s focus on high‑quality biosimilars and advanced manufacturing technologies positions it as a key player in the Asia‑Pacific market.

Sustainability & Growth Initiatives:

• Expansion of fermentation facilities in South Korea.
• Adoption of digital twin technology for process optimization.
• Partnerships with global pharma for pipeline development.

---

2️⃣ 9. Samsung Bioepis

Headquarters: Seoul, South Korea
Key Offering: Non‑glycosylated protein biologics for immunology and metabolic disorders

Samsung Bioepis focuses on innovative biologics and has accelerated its non‑glycosylated protein portfolio through strategic acquisitions and joint ventures.

Sustainability & Growth Initiatives:

• Investment in state‑of‑the‑art biomanufacturing plants.
• Commitment to zero‑waste production processes.
• Collaboration with global CDMOs for rapid scale‑up.

---

1️⃣ 10. Bristol Myers Squibb

Headquarters: New York, United States
Key Offering: Non‑glycosylated protein therapeutics for oncology and autoimmune diseases

Bristol Myers Squibb’s focus on precision oncology and immunotherapy aligns with the growing demand for non‑glycosylated proteins. The company’s robust pipeline and global reach support rapid market adoption.

Sustainability & Growth Initiatives:

• Expansion of production capacity in the US and Europe.
• Implementation of renewable energy across manufacturing sites.
• Strategic partnerships with academic research centers.

---

Download FREE Sample Report: https://www.24chemicalresearch.com/download-sample/265953/global-recombinant-nonglycosylated-protein-market

Get Full Report Here: https://www.24chemicalresearch.com/reports/265953/global-recombinant-nonglycosylated-protein-market

---

🌍 Outlook: The Future of Recombinant Non‑Glycosylated Protein Market

The recombinant non‑glycosylated protein market is poised for continued expansion driven by cost‑effective manufacturing, biosimilar growth, and increasing chronic disease prevalence. Key factors shaping the outlook include regulatory harmonization, technological advancements in protein engineering, and strategic partnerships across the biopharmaceutical value chain.

📈 Future Trends Shaping the Market

• Rapid scale‑up of E. coli and yeast expression systems to meet global demand.
• Adoption of AI‑driven protein design for enhanced stability and efficacy.
• Growth of biosimilar market with simplified regulatory pathways.
• Increased focus on sustainability and carbon‑neutral production.
• Expansion of Asia‑Pacific manufacturing hubs to capture emerging markets.